Biotech

0 256
Actinium Pharmaceuticals Inc ATNM Stock News

Actinium Pharmaceuticals Inc (NYSEMKT: ATNM)

Actinium pharmaceuticals (ATNM) on Tuesday announced the hiring of Steven Price, to serve as Vice President, Clinical and Commercial Strategy.





Mr. Price, an industry veteran will be responsible for leading the development and optimized programs for Iomab-B, including initiatives targeted at patients, physicians, and payors designated to support clinical development and pre-commercialization efforts.

Key Hiring Adds Depth To An Already Robust Management Team

Mr. Price will bring extensive industry experience to ATNM, delivering over 30 years of marketing and strategic leadership experience to the company. His work specializes in the oncology field with most recent experiences in immunotherapy focused on hematology at Merck and antibody-based therapeutics at Imclone Systems.

Prior to joining the ATNM team, Mr. Price most recently served as the Global Disease Lead at Merck, where he focused on Keytruda, an anti-PD-1 immuno-oncology antibody. In that capacity, he served as the commercial lead on the product development team and was responsible for maximizing physician acceptance, KOL development, market penetration, and new indication launch uptake. Additional experience includes a vast knowledge of pre-launch strategies, pre-market evaluations, strategy development, and strategic and product implementation initiatives.




At Imclone, Mr. Price served as the Associate Vice President, Global New Products Strategic Marketing, where he was responsible and successful at facilitating all commercial aspects of the new product pipeline. Imclone subsequently became a wholly owned subsidiary of Eli Lilly.

Commenting on the hiring, ATNM Executive Chairman, Sandeth Seth, stated, “Steve’s hiring represents another significant step in Actinium’s growth and one that I am most excited about. Steve brings to Actinium a significant amount of knowledge and experience specific to hematology and also has deep relationships that he curated in his 30 years in this field. I look forward to working with Steve and the rest of the Actinium team in building a great company that is focused on improving outcomes for patients.”

ANTM Platform

ATNM is efficiently executing on their clinical initiatives and continue to deliver impressive results. A biopharmaceutical company that is developing innovative targeted therapies for patients with cancers lacking an effective treatment option, ATNM’s proprietary platform is progressing diligently, utilizing monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill these cells safely and effectively.

ATNM’s lead product, Iomab-B is being designed and developed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, most commonly referred to as a bone marrow transplant. Currently, a bone marrow transplant serves as the only current potential cure for patients with blood-borne cancers, which often requires the use of chemotherapeutic treatments and total body irradiation that often results in significant toxicities.

ATNM is progressing in its single pivotal, 150-patient multi-center phase III clinical study of Iomab-B in patients with relapsed or refractory acute multiple myeloma in patients 55 years of age and over. Interim results are expected during 2017.

ATNM has a second promising clinical stage candidate, Actimab-A. Actimab-A is currently advancing its study in a multi-center, open label, 53 patient phase II trial for patients newly diagnosed with AML and are 60 years of age or older. Endpoints for this study are working to demonstrate the ability to induce remissions in elderly patients with AML who lack effective treatment options, especially for patients that may not have the ability to tolerate standard treatment options that introduce toxicities into the body.

Actimab-M, another product candidate, is being developed and studied in patients with relapsed or refractory multiple myeloma in a phase I clinical trial. ATNM is utilizing its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225, that are directed at various cancers that are blood-borne or form solid tumors in the body.

For continued breaking news coverage on Actinium pharmaceuticals, stay with CNA Finance, your source for all things ATNM.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 999
Delcath Systems, Inc. DCTH Stock News

Delcath Systems, Inc. (NASDAQ: DCTH)

Delcath Systms is having a great time in today’s trading session. When the opening bell rang, the stock was already trading well into the green. While there was a small correction shortly after the bell, the stock has made up for that and then some with the upward trend we’ve seen since. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to DCTH ahead.





What We’re Seeing From DCTH

As mentioned above, Delcath Systems is having an incredibly strong day in today’s trading session. When the opening bell rang, the stock was already trading on impressive gains. Shortly after the bell, we saw a bit of downward movement, but that didn’t last long. Since then, the stock has been on a solid upward trend. Currently (12:51), DCTH is trading at $0.22 per share after a gain of $0.06 per share (37.97%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our friends at Trade Ideas were the first to inform us of the gains on DCTH. When the CNA Finance team received the alert, we started digging to see why the stock was running upward. It didn’t take long to dig up the details. In this particular case, the gains are being caused by positive data released by the company early today.




The gains are the result of a presentation the company offered at the Regional Cancer Therapies 12th International Symposium in Snowbird, UT. The data surrounded Delcath Systems’ PHP therapy, which delivers a high dose of Melphalan directly to the liver. This is achieved through a catheter and takes about 30 minutes.

The data released surrounds 49 ocular melanoma patients that were treated over an 8-year period. These treatments took place across two cancer centers. Through the data, investors learned that the treatment proved to be effective. In fact, the data showed that 45.7% of the patients treated experienced a partial or complete response, leading to an overall survival rate of more than 3 years!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team is excited to follow DCTH. In particular, we’re interested in the company’s next steps with regard to its PHP therapy. We’ll continue to keep a close eye on the news surrounding the stock and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 294
Vermillion, Inc. VRML Stock News

Vermillion, Inc. (NASDAQ: VRML)

Vermillion is having an overwhelmingly strong day in the market today. In fact, when the trading session opened, the stock was already trading in the green. From there, it went on a tremendous spike upward before correcting and finding it’s support still well in the realm of gains. Below, we’ll talk about what we’re seeing from VRML, why, and what we’ll be watching for ahead.





What We’re Seeing From VRML

As mentioned above, Vermillion is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading slightly in the green. However, that didn’t last long as slight gains became massive ones early on. Nonetheless, after hitting an early morning peak, the stock corrected before finding support, still with nice gains. Currently (12:25), VRML is trading at $2.07 per share after a gain of $0.32 per share or 18.03% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on VRML. As soon as we received the alert, the CNA Finance team went to work to figure out exactly what was causing the movement. It took some digging to find the story, but we believe we found the reason for the gains.




The gains seem to be the result of excitement surrounding an SEC filing. Through the filing, investors learned that insider, Larry N. Feinberg just made a large purchase of the stock. In fact, he purchased 617,731 shares in a transaction dated February 17th. The average cost of the purchase came to $1.40 per share, bringing the total value of the insider buy to $864,823.40.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on VRML. After all, when an insider makes a large purchase on a stock, it shows confidence and can sometimes be a clue of positive news to come. Nonetheless, we’ll keep a close eye on the news surrounding the stock and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1166
Eyegate Pharmaceuticals Inc EYEG Stock News

EyeGate Pharmaceuticals Inc (NASDAQ: EYEG)

EyeGate Pharmaceuticals is having an overwhelmingly strong day in the market today. As soon as the market opened for the day, the stock was trading well into the green. Since then, we’ve seen some upward and some downward movement, but the stock has definitely been able to hold onto impressive gains. Below, we’ll talk about what we’re seeing from EYEG, why, and what we’ll be watching for ahead.





What We’re Seeing From EYEG

As mentioned above, EyeGate Pharmaceuticals is having an incredibly strong day in the market today. In fact, on the opening bell, the stock was trading well into the green. Since then, the stock has seen movement in both directions, but the gains are clearly here to stay. Currently (12:10), EYEG is trading at $2.47 per share after a gain of $0.84 per share (51.28%) thus far today.

Why The Stock Is Climbing

As is almost always the case, our partners at Trade Ideas were the first to notify us of the upward movement on EYEG. As soon as we received the alert, the CNA Finance team went to work to dig up the cause of the gains. It didn’t take long to find the story. Ultimately, the gains are the result of an announcement of a partnership that’s leading to quite a bit of investor excitement.




Early this morning, EyeGate Pharmaceuticals announced that it has partnered with Valeant Pharmaceuticals. The companies have entered into an exclusive, worldwide licensing agreement. Under the agreement, EYEG has granted a subsidiary of VRX exclusive, worldwide commercial and manufacturing rights to the EyeGate(R) II Delivery System as well as the EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EYEG. In particular, we’ll be watching the relationship between the company and VRX as it evolves, as not only does this bring in some revenue now, but it could also be a major driver of future revenue. We’ll keep a close eye on the news and bring it to you as it breaks!

Update (1:14): EYEG continues to soar. In fact, if it keeps going at this rate, it could double by the closing bell. At the moment, the stock is trading at $2.83 per share after a gain of $1.19 per share (72.57%) thus far.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 330
Momenta Pharmaceuticals, Inc. MNTA Stock News

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

Momenta Pharmaceuticals is having an incredibly rough day in the market today. As soon as the opening bell rang, the stock found itself deep in the red. Throughout the morning, we’ve seen some upward and some downward movement, but the losses seem to be here to stay. Below, we’ll talk about what we’re seeing from MNTA, why, and what we’ll be watching for ahead.





What We’re Seeing From MNTA

As mentioned above, Momenta Pharmaceuticals is having a pretty rough day in the market today. At the open of the trading session, the stock was already trading on dramatic losses. As the session progressed, we saw some upward and some downward movement, but the stock hasn’t been able to shake the big losses. At the moment (11:30), MNTA is trading at $15.96 per share after a loss of $3.04 per share or 16.03% thus far today.

Why The Stock Is Falling

As is almost always the case, our friends at Trade Ideas were the first to send the alert that MNTA was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story, the declines seem to be the result of concerns surrounding an FDA warning letter.




Early this morning, Momenta Pharmaceuticals announced that Pfizer, the contracted fill/finish manufacturing partner focused on Sandoz has received an FDA warning letter. While the letter does not restrict the production or shipment of the Glatopa 20 mg product, it is proving to be a major concern to investors as the facility that received the warning is a key part of the supply chain. As a result, we’re seeing big declines.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNTA. In particular, we’re watching for the company’s next steps as well as Pfizer’s response to the warning letter. Nonetheless, as always, we’ll keep a close eye on the news and be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 551
Cellect Biotechnology Ltd. APOP Stock News

Cellect Biotechnology Ltd. (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we’ve seen a continuation of strong movement. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to APOP ahead.





What We’re Seeing From APOP

As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we’ve seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story. The gains are ultimately the result of a positive data release.




Early this morning, Cellect Biotechnology released positive results from its clinical trial of ApoGraft(TM). The point of the study was to validate the company’s proprietary method for stem cell selection. To do so, the company went through the process of production and characterization through ApoGraft. In the announcement, investors learned that the company met its primary endpoint in this study.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on APOP. In particular, we’re following ongoing work with regard to ApoGraft as well as the rest of the company’s pipeline. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1081
Trevena Inc TRVN Stock News

Trevena Inc (NASDAQ: TRVN)

Trevena is having an incredibly rough day in the market today, which is surprising to many considering that the company released data showing that it met its primary endpoint in recent clinical studies. Below, we’ll talk about what we’re seeing from TRVN, why, and what we’ll be watching for ahead.





What We’re Seeing From TRVN

As mentioned above, Trevena is having a rough day in the market today. At the opening bell, the stock was already trading well into the red, even though it released information saying that primary endpoints were met. Nonetheless, the stock continues to trade on overwhelming losses. Currently (10:29), TRVN is trading at $4.88 per share after a loss of $2.25 per share (31.56%) thus far today.

Why The Stock Is Falling

As is always the case, our partners at Trade Ideas were the first to send us the alert about the losses on TRVN today. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. At first, we were surprised to find that the company released positive data from clinical studies today. However, from there, it didn’t take long to find the declines.




The dramatic decline in the stock is the result of notes by Adam Feuerstein. Feuerstein pointed out several concerns associated with the announcement. Most importantly, some of the doses of oliceridine demonstrated lower rates of depressed breathing verses morphine and the only statistically significant observation was found in the lowest dose. He also pointed out that the improved tolerability was not deemed to be statistically significant.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TRVN. In particular, we’ll be watching the coming NDA to the FDA, and we’re interested in seeing if what Feuerstein pointed out becomes a hurdle to the process. We’ll continue to keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 294
Cidara Therapeutics Inc CDTX Stock News

Cidara Therapeutics Inc (NASDAQ: CDTX)

Cidara Therapeutics is having an overwhelmingly rough start to the trading session today, and for good reason. Unfortunately, the company reported results from a recent Phase 2 trial, and those results weren’t up to par. Below, we’ll talk about what we’re seeing from the stock, the results that were reported, and what we can expect from CDTX ahead.





What We’re Seeing From CDTX

As mentioned above, Cidara Therapeutics is having an incredibly disappointing start to the trading session today. When the opening bell rang, the stock was already trading incredibly low thanks to the early morning data release. Since the bell, the stock has maintained losses. At the moment (9:50), CDTX is trading at $7.25 per share after a loss of $4.45 per share or 38.08% thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the declines on CDTX. As soon as we received the alert, the CNA Finance team started digging to see what was causing the movement. It didn’t take long to uncover the story. Unfortunately, the company missed the primary endpoint of a recent trial.




The trial was a controlled Phase 2 trial known as RADIANT During the trial Cidara Therapeutics was assessing the efficacy of echinocandin antifungal CD101 in women with moderate-to-severe acute VVC. Unfortunately, the efficacy trial showed that the treatment was not quite as effective as hoped. In a statement, Jeffrey Stein, Ph.D., President and CEO at CDTX, had the following to offer…

We are obviously disappointed with these results, which did not demonstrate the highly potent antifungal properties of CD101 against Candida we saw in preclinical animal models of VVC. While we believe that an improved topical formulation of CD101 could improve outcomes, at this time we have no plans for further development of CD101 topical in VVC…. We would like to thank the investigators and the patients who participated in this trial. This does not impact our development of CD101 IV for the treatment of Candidemia and invasive Candidiasis, for which animal models are well established and highly predictive of clinical outcomes.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CDTX. In particular, we’re interested in the company’s plans moving forward. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 2975
Peregrine Pharmaceuticals PPHM Stock News

Peregrine Pharmaceuticals (NASDAQ: PPHM)

Peregrine Pharmaceuticals is having an overwhelmingly strong day in the market today. When the trading session opened, the stock was already trading slightly in the green. However, as the trading session progressed, a good day quickly turned great. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to PPHM ahead.





What We’re Seeing From PPHM

As mentioned above, Peregrine Pharmaceuticals is having an incredibly strong day in the market today. After starting the session off slightly green, the stock quickly started to run for the top. After hitting a peak, it dipped a bit, but the gains are still incredible. At the moment (12:10), PPHM is trading at $0.60 per share after a gain of $0.16 per share (36.30%) thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on PPHM. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, the gains are the result of a data release.




Early this morning, Peregrine Pharmaceuticals released encouraging data from a proof-of-concept study it has been working on. The study surrounds the company’s cancer detection platform that’s based on cell-derived vesicles known as exosomes.

From the data release, we learned that the PPHM test was able to distinguish between healthy subjects and patients that had ovarian tumors. This was seen through levels of exosomes in plasma samples that contained phosphatidylserine. Investigators also proved the ability to distinguish between benign and malignant tumors. This was done based on an analysis of PS-positive exosome levels.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance will be watching PPHM incredibly closely. In particular, we’ll be watching the company’s work toward pushing this test to commercial stages. We’ll continue to follow the story and bring the news to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 637
Heat Biologics Inc HTBX Stock News

Heat Biologics Inc (NASDAQ: HTBX)

Heat Biologics is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. From there, we’ve seen some downward and some upward movement, but it’s clear that the stock is staying well away from the red. Below, we’ll talk about what we’re seeing from HTBX, why, and what we’ll be watching for ahead.





What We’re Seeing From HTBX

As mentioned above, Heat Biologics is having an incredibly strong day in today’s trading session. When the session started for the day, the stock was already trading on impressive gains. While we have seen a bit of downward movement since then, the stock is still holding onto impressive gains and is likely to stay in the green all day. At the moment (10:46), HTBX is trading at $0.99 per share after a gain of $0.03 per share or 4.19% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on HTBX. As soon as we received the alert, the CNA Finance team started working to see exactly what was causing the movement. It didn’t take long to dig up the story. The gains are the result of a presentation of clinical data.




Early this morning Heat Biologics announced that it has presented a poster of its immunologic data from its 94 patient Phase 2 trial of HS-410 either alone or in combination with BCG in patients with non-muscle invasive bladder cancer. The presentation was given at the 2017 Genitourinary (GU) Cancers Symposium. For more information with regard to the presentation, click here.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HTBX. In particular, we’ll be watching for news with regard to the ongoing work the company is doing on HS-410. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 744
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...